Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 318

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 318
---
 the accounting and financial reporting functions. These weaknesses could result in material misstatements not being prevented or detected
in a timely manner. Although the Company has taken certain remedial actions, there can be no assurance that the material weaknesses will
be fully remediated or that additional material weaknesses will not be identified in the future.

Risks Related to the Company’s Strategy to Grow the Business

The following risk factors reference the risks and uncertainties
relating to the growth strategy of OSR, which, following the closing of the Business Combination, relate to the growth strategy of the
Company going forward. References in this section to “we,” “us,” and “our” refer to OSR prior to the
closing of the Business Combination and to the Company after closing.

42

We may not be successful in our efforts to acquire, in-license or
discover and develop new product candidates.

The success of our business is highly dependent on our ability to successfully
identify new product candidates, whether through acquisitions or in-licensing transactions, or through our internal capabilities.
Our acquisition and in-licensing efforts focus on identifying assets in development by third parties across a diverse range
of therapeutic areas. Our strategy often entails designing optimal, efficient studies that result in quick “go/no-go” decisions
when deciding whether or how to proceed with future development for a given asset. We may decide to proceed with the development of a
drug candidate on this basis and later determine that the more costly and time intensive trials do not support the initial value the product
was thought to hold. Even if a product candidate does prove to be valuable, its value may be less than anticipated at the time of initial
investment. We may also face competition for attractive investment opportunities. A number of entities compete with us for such opportunities,
many of which have considerably greater financial and technical resources. If we are unable to identify a sufficient number of such product
candidates, or if the product candidates that we identify do not prove to be as valuable as anticipated, we will not be able to generate
returns and implement our investment strategy and our business and results of operations may suffer materially.

We currently have no marketing and sales organization for pharmaceutical
products and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these
capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and
sell our pharmaceutical products, we may not